Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
As of today, Pfizer(PFE) shares are valued at $25.00. The company's market cap stands at 142.14B, with a P/E ratio of 14.22 and a dividend yield of 7.0%.
On 2025-11-11, Pfizer(PFE) stock moved within a range of $24.36 to $25.01. With shares now at $25.00, the stock is trading +2.6% above its intraday low and -0.0% below the session's peak.
Trading activity shows a volume of 58.18M, compared to an average daily volume of 121.09M.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
PFE News
Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated. The next three years have...
Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Pfizer, retaining the price target of $32.00. Meet Your ETF AI Analyst Discover how TipRanks...
Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs. The market for GLP-1 drugs is already white-hot a...
Analyst ratings
58%
of 24 ratingsMore PFE News
Key Points Pfizer's sales and profits came in better than expected for the third quarter. The stock, however, remains down for the year. Concerns about the c...
The U.S. Department of Health and Human Services announced that the U.S. Food and Drug Administration is initiating the removal of broad “black box” warnings fr...
Metsera (MTSR) stock toppled Monday after the buyout battle with Pfizer (PFE) and Novo Nordisk (NVO) ended. Pfizer will acquire the small obesity-focused biotec...
Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late...
Danish drug giant Novo Nordisk’s shares rose modestly during early trading on Monday. This came after reports that Novo Nordisk’s pursuit of obesity market deal...
J.P. Morgan analyst Chris Schott has maintained their neutral stance on PFE stock, giving a Hold rating on November 6. Meet Your ETF AI Analyst Discover how Tip...
Pfizer (PFE) has reached a deal to buy Metsera (MTSR), a weight-loss drug startup, in a transaction that could total more than $10 billion. The agreement follow...